Fujifilm to accelerate the manufacturing of Avigan to treat COVID-19

By Akshay Kedari  | Date: 2020-04-16

Fujifilm to accelerate the manufacturing of Avigan to treat COVID-19

Fujifilm, a renowned Japanese pharmaceutical company, has reportedly announced plans to boost the production of Avigan, an antiviral drug said to be a possible therapy for coronavirus. Avigan is primarily used to treat Influenza.

The company is aiming to provide this drug in large quantities in order to meet the nationwide growing need for antiviral drugs. The company hopes to produce hundreds of thousands of Avigan doses during the coming months.

The drug maker is currently increasing its production capacity in its Toyoma facility to accelerate the production rate. Since the company is planning large-scale production for Avigan, it has created strategic collaborations with international and domestic firms to provide the raw material for manufacturing Avigan and has also added capacity at its Mako Pure Chemical Co. unit to manufacture active pharmaceutical ingredients of the drug.

Since Fujifilm will now have its massive production in place, it is expecting to produce 100,000 Avigan treatments courses ready for use by July. This number of 3.5 times Avigan’s supply in March and the company has further plans to manufacture 300,000 regimens in place by September.

Japanese drug maker, last month, stated its intentions to accelerate the production of Avigan, after the news made a global impact. However, the company also made some clarifications about its use. The company particularly specified that the Influenza treatment drug has never been distributed in any market and that it is not available in any pharmacies and hospitals across Japan as well as overseas.

Avigan is an antiviral drug developed by the Toyama Chemical unit of Fujifilm and it received approval for sale back in 2014 to treat influenza. However, it was told that this drug can only be used when all other treatments turn out to be ineffective against a re-emerging or novel influenza virus.

While talking about this drug, Shinzo Abe, the Prime Minister of Japan stated that the government would soon initiate tests of Avigan in coronavirus patients in collaboration with other nations and simultaneously accelerate the production while aiming a faster approval for the drug.

Source credit: https://www.fiercepharma.com/manufacturing/fujifilm-speeds-production-potential-covid-19-therapy-avigan

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Google Fi confirms data breach, leaking millions of customer’s data

Google Fi confirms data breach, leaking millions of customer’s data

By Akshay Kedari

Google Fi, Google's cell network operator, has reportedly revealed a data breach, which is most likely related to the T-recent Mobile's security disaster, which allowed hackers to leak millions of customers' personal information. The p...

European semiconductor giant ASML forecasts a sales surge for 2023

European semiconductor giant ASML forecasts a sales surge for 2023

By Akshay Kedari

Dutch semiconductor company ASML has reportedly forecast a revenue jump for the year 2023 as the global semiconductor industry anticipates a reacceleration of growth during the second half of this year. According to the firm, its net sales  f...

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

By Akshay Kedari

Following this funding, Interfor's long-term debt will hold a weighted average interest of 5.30% Interfor registered a Net Debt to the Invested Capital ratio of nearly 10% as of October 31, 2022 Interfor Corporation, one of the world...

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

By Akshay Kedari

Leading real estate services and investment company, ESR Group Limited, has recently announced that its exclusively-owned subsidiary, ARA and the Export-Import Bank of China have inked a breakthrough collaboration in a deal worth USD 1 billion infras...

Circularise nabs $11M to bring circular economy to industrial supply chains

Circularise nabs $11M to bring circular economy to industrial supply chains

By Akshay Kedari

Leading software platform, Circularise recently announced that it has raised $11.3 million (€11 million) in funding as part of its Series A round in a bid to advance its mission to bring a circular economy to industrial supply chains. The fun...